A single-arm study for 37 NSCLC patients with metastatic KRAS or EGFR mutations using Reolysin (an OV product based on Reovirus type 3) in combination with paclitaxel and carboplatin, compared favorably (the median progression-free survival (PFS) and overall survival (OS) were 4 months and 13.1 months, respectively) with previous studies for the chemotherapy-alone (171). Here, KRAS is linked to non-small cell lung carcinoma.